Transcription of Public Assessment Report Decentralised Procedure ...
{{id}} {{{paragraph}}}
Example: bachelor of science
Public Assessment Report Decentralised Procedure ...
PAR sayanaject 104 mg suspension for injection UK/H/5497/001/DC 1 Public Assessment Report Decentralised Procedure sayanaject 104 mg suspension for injection (Medroxyprogesterone acetate) Procedure No: UK/H/5497/001/DC UK Licence No: PL 00057/1498 Pfizer Limited PAR sayanaject 104 mg suspension for injection UK/H/5497/001/DC 2 LAY SUMMARY sayanaject 104 mg suspension for injection (medroxyprogesterone acetate, suspension for injection, 104 mg) This is a summary of the Public Assessment Report (PAR) for sayanaject 104 mg suspension for injection (PL 00057/1498; UK/H/5497/001/DC). It explains how sayanaject 104 mg suspension for injection was assessed and its authorisation recommended, as well as its conditions of use.
PAR Sayanaject 104 mg suspension for injection UK/H/5497/001/DC 3 during the first 5 days of their normal menstrual cycle. After childbirth: If the patient uses Sayanaject 104 mg suspension for injection after having a baby and
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: